DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04375514 (ClinicalTrials.gov)	August 10, 2020	30/4/2020	Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis	A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients With Cystic Fibrosis	Cystic Fibrosis, Pulmonary	Drug: ARO-ENaC;Drug: Placebo	Arrowhead Pharmaceuticals	NULL	Recruiting	18 Years	55 Years	All	54	Phase 1;Phase 2	Australia;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04375514
(ClinicalTrials.gov)

August 10, 2020

30/4/2020

Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients With Cystic Fibrosis

Cystic Fibrosis, Pulmonary

Drug: ARO-ENaC;Drug: Placebo

Arrowhead Pharmaceuticals

NULL

Recruiting

18 Years

55 Years

All

Phase 1;Phase 2

Australia;New Zealand